Anexelekto (AXL) Increases Resistance to EGFR-TKI and Activation of AKT and ERK1/2 in Non-Small Cell Lung Cancer Cells

Yaqiong Tian,*1 Zengli Zhang,†1 Liyun Miao,* Zhimin Yang,‡ Jie Yang,* Yinhua Wang,§ Danwen Qian,¶ Hourong Cai,* and Yongsheng Wang*

*Department of Respiratory Medicine, Drum Tower Hospital Affiliated to Medical School of Nanjing University, Nanjing, China
†Department of Respiratory Diseases, The Second Affiliated Hospital of Soochow University, Suzhou, China
‡Department of Medical Oncology, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui Province, China
§Department of Oncology, Wuhu No.2 People’s Hospital, Wuhu, Anhui Province, China
¶Department of Oncology, Nanjing Red Cross Hospital, Nanjing, Jiangsu Province, China

Recently, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have revolutionized non-small cell lung cancer (NSCLC) treatment. However, resistance remains a major obstacle. Anexelekto (AXL) is a member of receptor tyrosine kinases (RTKs) and shares the same downstream signaling pathways with EGFR, such as PI3K/AKT and MAPK/ERK. AXL overexpression in resistant tumors has been implicated in many previous studies in vitro and in vivo. In this study, we further examined whether expression of AXL and its downstream targets increased in gefitinib-resistant PC9 cells (PC9GR). In addition, we hypothesize that knocking down AXL in PC9GR and overexpressing AXL in PC9 using genetic tools can restore and decrease the sensitivity to gefitinib, respectively. We found that silencing AXL could sensitize the resistance to gefitinib, and the downstream pathways were significantly inhibited. Interestingly, we also discovered that increased AXL expression did promote the resistance, and its downstream targets were activated accordingly. Then 69 NSCLC patients who harbored EGFR mutation were recruited to analyze the expression of AXL and the association between AXL expression and clinical characteristics. We found that 5 of the 69 patients were AXL positive (about 7%), and AXL was related to tumor differentiation and tumor size. In this study, we concluded that the molecular mechanisms of AXL mediated resistance involved in the increased activity of the PI3K/AKT and MAPK/ERK1/2 pathways, and AXL overexpression could promote resistance, but it can be weakened when AXL expression is silenced.

Key words: Anexelekto (AXL); Non-small cell lung cancer (NSCLC); Epidermal growth factor receptor (EGFR); Resistance

INTRODUCTION

Lung cancer is the leading cause of cancer-related deaths worldwide (1). Even though some progress has been made in its treatment, the average overall 5-year survival rate is still as low as 17.1% (2). The discovery of epidermal growth factor receptor (EGFR) mutation is a milestone in the treatment of lung cancer. Patients who harbor the EGFR-activated mutation can be targeted by the EGFR-tyrosine kinase inhibitor (TKI) such as classical gefitinib and erlotinib, which can prolong progression-free survival (PFS) of the patients. The mutation rate is approximately 20% in Caucasians, but for Asians, their mutation rate can reach 30% or more (3). Despite the fact that EGFR-TKI is significantly effective at the beginning of treatment, almost all patients develop resistance after 10 to 14 months of treatment. However, there are still 20–30% of patients who have a poor response because of primary or intrinsic resistance to EGFR-TKIs (4,5). Moreover, the current standard practice is to switch to traditional cytotoxic chemotherapy when the patients develop resistance. At present, the elucidated mechanisms of resistance include secondary T790M mutation in 20 exons and amplification of c-met (6–8), but approximately 30% of patients who obtain resistance cannot be explained through the mechanisms above.

In 2012, Zhang et al. demonstrated that the activation of anexelekto (AXL) kinase, one member of the receptor tyrosine kinases (RTKs), can cause resistance to...
EGFR-TKI in lung cancer (9). Before this discovery in lung cancer, AXL-mediated resistance had been reported in many other kinds of cancers, such as a tyrosine kinase switch from KIT to AXL mediated imatinib resistance in gastrointestinal stromal tumor (GIST) cells (10), lapatinib resistance in HER2-positive breast cancer (11), erlotinib resistance in head and neck cancer (HNC) cells (12), and nilotinib resistance in chronic myelocytic leukemia (CML) (13). A study from Korea observed that increased AXL expression was approximately 19% in the patients who had a good initial response and then developed resistance (14). Another Korean study revealed that AXL can also mediate primary resistance in non-small cell lung cancer (NSCLC) (15). However, the particular molecular mechanisms of the resistance have not been stated clearly, so the aim of this study is to investigate the specific mechanisms.

AXL was originally isolated from patients with CML in 1988 (16), and it is a member of the TAM RTK family, which includes Tyro3, AXL, and Mer. AXL is a transmembrane protein with a molecular weight of about 140 kDa. A unique extracellular domain that consists of two N-terminal immunoglobulin (Ig)-like domains and dual fibronectin type III (FNIII) repeats is responsible for the interaction between the cells. Growth arrest-specific 6 (Gas6), a vitamin K-dependent protein, is the ligand of AXL. AXL activation through Gas6 binding or independent of Gas6 both can activate its downstream targets, mainly including tyrosine phosphorylation of PI3K/AKT and MAPK/ERK1/2 pathways (17,18). The downstream signaling cascades of AXL are closely related to anti-apoptotic effect (19), and progression and development of tumors (20,21). AXL overexpression has been found in many kinds of cancers such as breast cancer, gastric cancer, prostate cancer, ovarian cancer, and lung cancer. The purpose of this study is to clarify the specific mechanism of AXL-mediated resistance to overcome the resistance in NSCLC.

MATERIALS AND METHODS

Cell Lines and Cell Culture

PC9 [EGFR exon 19 deletion (delE746-A750)] and its gefitinib-resistant cell line PC9GR were gifts from the Shanghai Pulmonary Hospital, Tongji University, China. Both were cultured in DMEM growth medium (Gibco), supplemented with 10% fetal bovine serum (FBS; Gibco) and 1x penicillin-streptomycin solution (Thermo) at 37°C in a humidified 5% CO2 incubator. Gefitinib was purchased from Risheng Technology Co. (Wuhan, China). It was dissolved in dimethyl sulfoxide (DMSO) at 10 mM and stored at −20°C. All antibodies were purchased from Cell Signaling Technology, except the antibody to AXL, which was purchased from R&D Systems.

Cell Viability Assay

To perform the MTT assay, 3,000 to 3,500 cells per well were plated in 96-well sterile plastic plates and allowed to attach overnight; the cells were then exposed to different concentrations of gefitinib for 72 h, and 20 μl thiazolyl blue (MTT) was added in each well. After incubation for 4 h at 37°C, the supernatant was removed and 150 μl DMSO was placed in each well to dissolve formazan for 10 min with gentle shaking at room temperature. Absorbance at 490 nm was determined on a microplate reader (Model 680; Bio-Rad), and percentage of inhibition of cell population growth was calculated relative to untreated controls: Percentage of inhibition = 100% × (OD490 (untreated controls) − OD490 (treated cells))/OD490 (untreated controls). Six duplications were set at each drug concentration, the average value after removing the maximum and minimum was used for analysis.

Western Blotting

For Western blotting, whole-cell lysates were extracted. Total proteins were separated on 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) gels and then transferred onto polyvinylidene difluoride (PVDF) membranes, blocked with 5% nonfat milk in TBST, and incubated with primary antibody at room temperature for 4 h or overnight at 4°C. After incubation with horseradish peroxidase (HRP)-conjugated secondary antibody for 1.5 h, protein expression was detected using ECL (Millipore).

Quantitative RT-PCR

Total RNA was extracted with TRIzol reagent (Takara). For quantitative reverse transcription polymerase chain reaction (RT-PCR) analysis of mRNA expression, 0.5 μg of total RNA was reverse transcribed into cDNA in 10 μl of reaction system using a reverse transcription kit (#A036; Takara). Real-time PCR was conducted on ABI StepOnePlus using SYBR mix agents (#420; Takara). Expression of AXL was relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA calculated by the 2−ΔΔCt method.

Transfection

For AXL stable silencing and upregulation, PC9GR and PC9 parental cells were transfected with lentivirus-based gene transduction method to knock out and over-express AXL, respectively. After transfection for 72 h, the green fluorescence was observed to roughly judge the transfection efficiency, and the proteins and total RNA were extracted from the cells for further analysis. The
lentivirus vector of targeted gene and nontargeting control was constructed by GenChem (Shanghai, China).

**Immunohistochemical Staining**

Formalin-fixed, paraffin-embedded blocks of tumors between 2013 and 2014 were obtained from the pathology archives of Drum Tower Hospital, Affiliated to the Medical School of Nanjing University. Informed consent was obtained from all patients, and this study was approved by the ethics committee of the Medical School of Nanjing University. Immunohistochemical staining for AXL and hematoxylin-eosin staining were performed. Sections were cut at 4 μm and deparaffinized in xylene, and then rehydrated by using graded alcohols. Endogenous peroxidase was quenched with aqueous 3% hydrogen peroxide for 15 min, and then antigen retrieval was performed in a pressure cooker. The primary antibody was incubated overnight at 4°C. A PBST wash was followed by the incubation of HRP-conjugated secondary antibody. Finally, 3,3'-diaminobenzidine (DAB) tetrahydrochloride was applied as a chromogen to visualize positive tissues. All specimens were scored independently by two board-certified pathologists. The average score of two pathologists was used for analysis.

**Statistical Analysis**

Differences between two groups were assessed by Student's *t*-test. The association between AXL expression...
and clinical factors was tested using chi-square or Fisher’s exact tests. Statistical analysis was performed using SPSS version 16.0 for Windows. The data are presented as mean ± SD for the indicated number of independently performed experiments. The result was considered to be statistically significant with a value of \( p < 0.05 \). All statistical tests were two sided.

**RESULTS**

Increased expression of AXL was accompanied by activation of downstream signaling pathways in resistant cells. PC9GR cells were established through chronic exposure to gefitinib in vitro, and the resistance was confirmed before being used in the experiment. The median inhibitory concentration (IC\(_{50}\)) of PC9GR was 8.02 ± 2.13 μg/ml, about 870-fold higher than the IC\(_{50}\) of parental PC9 (9.22 ± 1.09 ng/ml) (Fig. 1C), which is sensitive to gefitinib. The phenomenon proved that PC9GR cells used in this experiment did develop resistance to gefitinib. Then we found that AXL expression was higher in PC9GR cells than in parental PC9, and the phosphorylation levels of its downstream signaling targets AKT and ERK were elevated correspondingly (Fig. 1A and B). The results demonstrated that AXL-mediated acquired resistance to EGFR-TKI may be associated with activation of PI3K/AKT and MAPK/ERK1/2 pathways.

**Silencing of AXL Weakens the Resistance to Gefitinib**

Because AXL was overexpressed in the resistant cells, we hypothesized that knocking out AXL gene in PC9GR
by small interfering RNA would reestablish the sensitivity to gefitinib. We used the lentivirus-based gene silencing method to stably knock down the gene expression of AXL (siAXL), and a nontargeting control was used. After transfection for 72 h according to the instructions, the knockout efficiency confirmed by RT-PCR reached at least 70% (Fig. 2C). In accordance with our hypothesis, AXL and its downstream targets, phospho-AKT (p-AKT) and phospho-ERK1/2 (p-ERK1/2), were significantly decreased after knocking out AXL (Fig. 2A and B). We expectedly found that the sensitivity of the siAXL group cells to gefitinib was improved relative to control group cells (Fig. 2D). Furthermore, the IC50 of the siAXL group was also lower than that of the control group (Fig. 2E). These results indicated that silencing AXL sensitizes the resistance to the specific TKI mainly through downregulating the phosphorylation levels of its downstream signaling targets.

**Overexpression of AXL Triggered the Formation of Acquired Resistance**

In order to more fully understand the influence of AXL to acquired resistance, we constructed a lentivirus-based expression vector to upregulate AXL expression in sensitive PC9 cells (upAXL), and also a nontargeting control (control) was used. Lentivirus and PC9 were incubated together for 72 h followed by RT-PCR, which was performed to verify the transfection efficiency (Fig. 3C). Our results displayed that the phosphorylation levels of AXL downstream targets were obviously upregulated accordingly after AXL was stably overexpressed (Fig. 3A and B). Interestingly, the drug sensitivity to

**Figure 3.** AXL can drive the acquired resistance. (A, B) Prior to immunoblotting for indicated proteins, PC9 cells were transfected for 72 h to upregulate AXL. (C) RT-PCR was conducted to verify the transfection efficiency. (D, E) MTT assay was performed to detect the cell viability. IC50 was calculated by SPSS, and data are presented as mean±SD. *p<0.05.
gefitinib determined by MTT detected that the IC\textsubscript{50} of upAXL cells (42.96 ± 11.17 ng/ml) increased nearly threefold relative to the control group (14.79 ± 2.23 ng/ml) (Fig. 3D and E). These results confirmed that AXL can promote acquired resistance to gefitinib via the activation of PI3K/AKT and MAPK/ERK1/2 pathways in NSCLC.

**AXL Was Related to Tumor Differentiation and Volume in Patients**

Sixty-nine patients who harbored the EGFR mutation were enrolled to evaluate the association between AXL expression decided by immunohistochemistry and clinical characteristics. The characteristics of the patients and statistical results are shown in Table 1. Observation under a microscope found that AXL was densely expressed on cell membrane and but scarcely in the cytoplasm (Fig. 4A and B). Roughly consistent with some previous studies (15), the positive rate of AXL in our study was approximately 7%. We found that the status of AXL had no relation to patients’ age, gender, smoking history, mutation type of EGFR, or tumor stage. However, positive AXL expression was strongly associated with poor tissue differentiation of tumors in this study. In addition, we

| Patient Characteristics | Negative (%) | Positive (%) | p Value |
|-------------------------|--------------|--------------|---------|
| Age                     |              |              | 0.763   |
| <65                     | 40 (62.5)    | 4 (80)       |         |
| ≥65                     | 24 (37.5)    | 1 (20)       |         |
| Gender                  |              |              | 0.763   |
| Female                  | 40 (62.5)    | 4 (80)       |         |
| Male                    | 24 (37.5)    | 1 (20)       |         |
| Smoking history         |              |              | 1.000   |
| Never smoker            | 48 (75.0)    | 4 (80)       |         |
| Former/current smoker   | 16 (25.0)    | 1 (20)       |         |
| Mutation type           |              |              | 1.000   |
| 19Del                   | 31 (48.4)    | 2 (40)       |         |
| L858R                   | 33 (51.6)    | 3 (60)       |         |
| Tissue differentiation  |              |              | <0.05   |
| Poor                    | 9 (14.1)     | 5 (100)      |         |
| Moderate                | 42 (65.6)    | 0            |         |
| Well                    | 13 (20.3)    | 0            |         |
| Stage                   |              |              | 0.122   |
| I–II                    | 42 (65.6)    | 1 (20)       |         |
| III–IV                  | 22 (34.4)    | 4 (80)       |         |

Patients’ clinical characteristics and AXL expression status are presented. The difference between patients’ characteristics and AXL expression was evaluated by chi-square test (\(p<0.05\)).

**Figure 4.** AXL was related to tumor volume. (A, B) Negative and positive staining examples for AXL are exhibited, respectively. Pictures were taken under 200-fold amplification. (C) Tumor volume (\(cm^3\)) = length \times width \times height. The difference between negative and positive was evaluated by Student’s t-test. *\(p<0.05\).
AXL increases resistance to EGFR-TKI in NSCLC

In 2013, the first AXL inhibitor, BGB324, entered clinical trials (30). It predicted that AXL may be a promising and important target to overcome resistance. Many researchers also found that they could achieve the same goal to inhibit AXL in aspects other than specific AXL inhibition. For example, our previous study proved that targeting AXL altered microRNAs, such as miR-374a and miR-548b, and may also provide a therapeutic method to overcome gefitinib resistance in NSCLC (31). AUY92, a newly developed non-geldanamycin class HSP90 inhibitor, can effectively overcome MET- and AXL-mediated EGFR-TKI resistance in lung cancer cells (32). We can also accelerate the degradation of AXL to reverse the resistance in NSCLC (33).

The results of the case analysis in our study are barely satisfactory. The limitations mainly lie in the small sample size and the difficulty in obtaining the tissues again when patients develop resistance. For these reasons, much more clinical research needs to be done to explore the role of AXL to resistance. Our study concluded that AXL can trigger the generation of resistance, and inhibition of AXL did weaken the resistance. The effect of AXL-mediated resistance was mainly determined by the activation of its downstream signaling pathways, PI3K/AKT and MAPK/ERK1/2. From what is mentioned above, we concluded that AXL is a promising target to reverse resistance to EGFR-TKI in NSCLC.

ACKNOWLEDGMENTS: Financial support of this work was from the National Natural Science Foundation of China (Grant Nos. 81301882 and 81172240).

REFERENCES

1. Siegel, R.; Ma, J.; Zou, Z.; Jemal, A. Cancer statistics. CA Cancer J. Clin. 64:9–29; 2014.
2. Siegel, R.; DeSanctis, C.; Virgo, K.; Stein, K.; Mariotto, A.; Smith, T.; Cooper, D.; Gansler, T.; Lerro, C.; Fedewa, S.; Lin, C.; Leach, C.; Cannady, R. S.; Cho, H.; Scoppa, S.; Hachey, M.; Kirch, R.; Jemal, A.; Ward, E. Cancer treatment and survivorship statistics. CA Cancer J. Clin. 64:220–241; 2012.
3. Rosell, R.; Moran, T.; Queralt, C.; Porta, R.; Cardenal, F.; Camps, C.; Majem, M.; Lopez-Vivanco, G.; Isla, D.; Provencio, M.; Insa, A.; Massuti, B.; Gonzalez-Larriba, J. L.; Paz-Ares, L.; Bover, I.; Garcia-Campelo, R.; Moreno, M. A.; Catot, S.; Rolfo, C.; Reguart, N.; Palmero, R.; Sanchez, J. M.; Bastus, R.; Mayo, C.; Bertran-Alamillo, J.; Molina, M. A.; Sanchez, J. J.; Taron, M. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 362:220–241; 2010.
4. Jackman, D. M.; Miller, V. A.; Cioffi, R. A.; Yeap, B. Y.; Janne, P. A.; Riely, G. J.; Ruiz, M. G.; Giaccone, G.; Sequist, L. V.; Johnson, B. E. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: Results of an online tumor registry of clinical trials. Clin. Cancer Res. 15:5267–5273; 2009.
5. Costa, D. B.; Kobayashi, S.; Tenen, D. G.; Huberman, M. S. Pooled analysis of the prospective trials of gefitinib...
monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer 58:95–103; 2007.

6. Pao, W.; Miller, V. A.; Politi, K. A.; Riely, G. J.; Somwar, R.; Zakowski, M. F.; Kris, M. G.; Varmus, H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2:e73; 2005.

7. Arcila, M. E.; Oxnard, G. R.; Nafa, K.; Riely, G. J.; Ladanyi, M. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin. Cancer Res. 17:1169–1180; 2011.

8. Sequist, L. V.; Waltman, B. A.; Dias-Santagata, D.; Digumarthy, S.; Turke, A. B.; Fidias, P.; Bergethon, K.; Shaw, A. T.; Gettinger, S.; Copser, A. K.; Akhavanfard, S.; Heist, R. S.; Temel, J.; Christensen, J. G.; Wain, J. C.; Lynch, T. J.; Vernovsky, K.; Mark, E. J.; Lanutti, M.; Iafrate, A. J.; Mino-Kenudson, M.; Engelman, J. A. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3:75ra26; 2011.

9. Zhang, Z. F.; Lee, J. C.; Lin, L. P.; Olivas, V.; Au, V.; LaFramboise, T.; Abdel-Rahman, M.; Wang, X. Q.; Levine, A. D.; Rho, J. K.; Choi, Y. J.; Choi, C. M.; Kim, S. W.; Iafrate, A. J.; Park, Y. S.; Kim, W. S.; Lee, H. D.; Lee, J. S.; Miller, V. A.; Arcila, M.; Ladanyi, M.; Moonsamy, P.; Sawyers, C.; Boggon, T. J.; Ma, P. C.; Costa, C.; Taron, M.; Rosell, R.; Halmos, B.; Bivona, T. G. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat. Genet. 44:852–860; 2012.

10. Mahadevan, D.; Cooke, L.; Riley, C.; Swart, R.; Simons, B.; Della Croce, K.; Wisner, L.; Iorio, M.; Shakalya, K.; Garewal, H.; Nagle, R.; Bears, D. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene 26:3909–3919; 2007.

11. Liu, L.; Greger, J.; Shi, H.; Liu, Y.; Greshock, J.; Annan, R.; Halsey, W.; Sathe, G. M.; Martin, A. M.; Gilmer, T. M. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: Activation of AXL. Cancer Res. 69:6871–6878; 2009.

12. Giles, K. M.; Kalinowski, F. C.; Candy, P. A.; Epis, M. R.; Zhang, P. M.; Redfern, A. D.; Stuart, L. M.; Goodall, G. J.; Leedman, P. J. Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib. Mol. Cancer Ther. 12:2541–2558; 2013.

13. Hong, C. C.; Lay, J. D.; Huang, J. S.; Cheng, A. L.; Tang, J. L.; Lin, M. T.; Lai, G. M.; Chuang, S. E. Receptor tyrosine kinase Axl is induced by chemotherapy drugs and overexpression of Axl confers drug resistance in acute myeloid leukemia. Cancer Lett. 268:314–324; 2008.

14. Ji, W.; Choi, C. M.; Rho, J. K.; Jang, S. J.; Park, Y. S.; Chun, S. M.; Kim, W. S.; Lee, J. S.; Kim, S. W.; Lee, D. H.; Lee, J. C. Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer. BMC Cancer 13:606; 2013.

15. Kim, G. W.; Song, J. S.; Choi, C. M.; Rho, J. K.; Kim, S. Y.; Jang, S. J.; Park, Y. S.; Chun, S. M.; Kim, W. S.; Lee, J. S.; Kim, S. W.; Lee, D. H.; Lee, J. C. Multiple resistant factors in lung cancer with primary resistance to EGFR-TK inhibitors confer poor survival. Lung Cancer 88:139–146; 2015.

16. Janssen, J. W. G.; Schulz, A. S.; Steenwoorden, A. C. M.; Schmidberger, M.; Strehl, S.; Ambros, P. F.; Bartram, C. R. A novel putative tyrosine kinase receptor with oncogenic potential. Oncogene 6:2113–2120; 1991.

17. Lee, W. P.; Wen, Y.; Varmus, B.; Hung, M. C. Akt is required for Axl-Gas6 signaling to protect cells from E1A-mediated apoptosis. Oncogene 21:329–336; 2002.

18. Hong, C. C.; Lay, J. D.; Huang, J. S.; Cheng, A. L.; Tang, J. L.; Lin, M. T.; Lai, G. M.; Chuang, S. E. Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Lett. 268:314–324; 2008.

19. Bellota, P.; Zhang, Q.; Goff, S. P.; Basilico, C. Signaling through the ARK tyrosine kinase receptor protects from apoptosis in the absence of growth stimulation. Oncogene 15:2387–2397; 1997.

20. Goruppi, S.; Rauo, E.; Schneider, C. Gas6, the ligand of Axl tyrosine kinase receptor, has mitogenic and survival activities for serum starved NIH3T3 fibroblasts. Oncogene 12:471–480; 1996.

21. Goruppi, S.; Rauo, E.; Varmus, B.; Schneider, C. Requirement of phosphatidylinositol 3-kinase-dependent pathway and Src for Gas6-Axl mitogenic and survival activities in NIH3T3 fibroblasts. Mol. Cell. Biol. 17:4442–4453; 1997.

22. Byers, L. A.; Diao, L. X.; Wang, J.; Saintigny, P.; Girard, L.; Peyton, M.; Shen, L.; Fan, Y. H.; Giri, U.; Tumula, P. K.; Nilsson, M. B.; Gudikote, J.; Tran, H.; Card nell, R. J. G.; Bears, D. J.; Warner, S. L.; Foulks, J. M.; Kanner, S. B.; Gandhi, V.; Krett, N.; Rosen, S. T.; Kim, E. S.; Herbst, R. S.; Blumenschein, G. R.; Lee, J. J.; Lippman, S. M.; Ang, K. K.; Mills, G. B.; Hong, W. K.; Weinstein, J. N.; Wistuba, II; Coombes, K. R.; Minna, J. D.; Heymach, J. V. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin. Cancer Res. 19:279–290; 2013.

23. Wilson, C.; Ye, X.; Pham, T.; Lin, E.; Chan, S.; McNamara, E.; Neve, R. M.; Belmont, L.; Koeppen, H.; Yauch, R. L.; Ashkenazi, A.; Settleman, J. Axl inhibition sensitizes mesenchymal cancer cells to antimitotic drugs. Cancer Res. 74:5878–5890; 2014.

24. Linger, R. M.; Cohen, R. A.; Cummings, C. T.; Sather, S.; Migdal-Wilson, J.; Middleton, D. H.; Lu, X.; Baron, A. E.; Franklin, W. A.; Merrick, D. T.; Jedlicka, P.; DeRyckere, D.; Heasley, L. E.; Graham, D. K. Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer. Oncogene 32:3420–3431; 2013.

25. Rho, J. K.; Choi, Y. J.; Kim, S. Y.; Kim, T. W.; Choi, E. K.; Yoon, S. J.; Park, B. M.; Park, E.; Bae, J. H.; Choi, C. M.; Lee, J. C. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation. Cancer Res. 74:2523–2524; 2014.

26. Brand, T. M.; Iida, M.; Stein, A. P.; Corrigan, K. L.; Braverman, C. M.; Luthar, N.; Toulany, M.; Gill, P. S.; Salgia, R.; Kimple, R. J.; Wheeler, D. L. AXL mediates resistance to cetuximab therapy. Cancer Res. 74:5152–5164; 2014.

27. Harbinski, F.; Craig, V. J.; Sanghavi, S.; Jeffery, D.; Liu, L. J.; Sheppard, K. A.; Wagner, S.; Stamm, C.; Buness, A.; Chatenay-Rivauday, C.; Yao, Y.; He, F.; Lu, C. X.; Guanovano, V.; Metz, T.; Finan, P. M.; Hofmann, F.; Sellers, W. R.; Porter, J. A.; Myer, V. E.; Graus-Porta, D.; Wilson, C. J.; Buckler, A.; Tiedt, R. Rescue screens with secreted
proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth. Cancer Discov. 2:948–959; 2012.
28. Yamaguchi, H.; Chang, S. S.; Hsu, J. L.; Hung, M. C. Signaling cross-talk in the resistance to HER family receptor targeted therapy. Oncogene 33:1073–1081; 2014.
29. Meyer, A. S.; Miller, M. A.; Gertler, F. B.; Lauffenburger, D. A. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells. Sci. Signal. 6:14; 2013.
30. Sheridan, C. First Axl inhibitor enters clinical trials. Nat. Biotechnol. 31:775–776; 2013.
31. Wang, Y.; Xia, H.; Zhuang, Z.; Miao, L.; Chen, X.; Cai, H. Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer. Cell Death Dis. 5:11; 2014.
32. Choi, Y. J.; Kim, S. Y.; So, K. S.; Baek, I. J.; Kim, W. S.; Choi, S. H.; Lee, J. C.; Bivona, T. G.; Rho, J. K.; Choi, C. M. AUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cells. PLoS One 10:e0119832; 2015.
33. Bae, S. Y.; Hong, J. Y.; Lee, H. J.; Park, H. J.; Lee, S. K. Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer. Oncotarget 6(12):10146–10160; 2015.